POULTRY 
Making MG protection safer and easier
1 vaccine up to 3 immunities
Less is more
- Less handling
- Less stress
- Less use of antibiotics
- More uniformity
- More protection
- Greater profitability
Efficacy of Vectormune FP MG against mycoplasma gallisepticum
One group of 8-week-old SPF chickens was vaccinated with Vectormune FP MG by air.
2 other groups were not vaccinated and were used as positive or negative controls.
Twelve weeks after vaccination, these groups were tested for pathogenic Mycoplasma gallisepticum.
Efficacy of Vectormune FP MG (AE) against Mycoplasma gallisepticum
In this comparative trial, 2 groups of SPF chickens were vaccinated at 8 weeks of age with Vectormune FP MG (AE) via a wing.
A third group of SPF chickens received a live vaccine by eye drop.
Vaccine uptakes were assessed 7 to 10 days after vaccination. 3 weeks after vaccination, a challenge test with Mycoplasma gallisepticum was performed and protection was assessed on the basis of clinical signs of MG such as tracheal rales, nasal discharge or cough in addition to the air sac score (0-4).
Efficacy of Vectormune FP MG against the avian influenza virus A group of 8-week-old SPF chickens were vaccinated with Vectormune FP MG by air.
In a laboratory trial, SPF chickens were vaccinated at 8 weeks of age with Vectormune® FP-MG + AE via wing web.
Seven to ten days after vaccination, the vaccine “takes” were evaluated.
Three weeks post-vaccination, challenge with Fowl Pox virus and Avian Encephalomyelitis virus were carried out.
Efficacy of Vectormune FP MG (AE) against avian encephalomyelitis virus
Vectormune offers a high level of protection against avian pox Vectormune FP MG (AE) and avian encephalomyelitis.
Benefits of Vectormune FP MG and Vectormune FP MG (AE)
- One injection in the wings to protect against up to 3 diseases (reduces the number of vaccinations and handling of birds).
- Effective and safe for layers, breeders and turkeys (safe use in turkeys, no reactions or complications after vaccination).
- Spread of MG to other flocks (vaccine does not contain live Mycoplasma-like organisms).
- Compatible with antibiotic therapy programmes.
- No interference with serological monitoring of MG (no seroconversion after vaccination).
